Cabaletta Bio, Inc. Common Stock (CABA) Stock
NASDAQ · CABA
Key stats
- Market cap
- $312.79M
- Price / Earnings ratio
- -1.7x
- EPS (TTM)
- -$1.36
- Volume
- Loading
- 52-week high
- $4.23
- 52-week low
- $1.18
Source: third-party data provider, as of November 13, 2026
Compare with CABA
Recent news

Zacks Investment Research
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
CABAMay 20, 2026
Zacks Investment Research
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
CABA

Zacks Investment Research
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
CABAMay 18, 2026
Zacks Investment Research
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
CABA

Stocktwits
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial
CABAMay 4, 2026
Stocktwits
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial
CABA

Business Wire
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
CABAApril 28, 2026
Business Wire
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
CABA
Technical indicators
- RSI 14
- 41.20
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- -0.19
- MACD histogram
- 0.04
- SMA 50
- $2.02
- Price below SMA 50
- EMA 50
- $1.90
- Price below EMA 50
- SMA 200
- $2.81
- Price below SMA 200
- EMA 200
- $2.52
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Strong Sell0
Sell0
Hold1
Buy2
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2021
2022
2023
2024
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2021
2022
2023
2024
2025
304M201M100M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-167.9M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Zacks Investment Research
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
CABAMay 20, 2026
Zacks Investment Research
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
CABA

Zacks Investment Research
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
CABAMay 18, 2026
Zacks Investment Research
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
CABA

Stocktwits
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial
CABAMay 4, 2026
Stocktwits
CABA Stock On Track For Best Day In 6 Months After Positive Early Results From Cell Therapy Trial
CABA

Business Wire
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
CABAApril 28, 2026
Business Wire
Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel
CABA

Business Wire
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
CABAApril 14, 2026
Business Wire
First Patients Dosed with Cabaletta Bio's Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform
CABA

Zacks Investment Research
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know
CABAMarch 6, 2026
Zacks Investment Research
Cabaletta Bio (CABA) Upgraded to Buy: Here's What You Should Know
CABA

Zacks Investment Research
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?
CABAJanuary 30, 2026
Zacks Investment Research
What Makes Cabaletta Bio, Inc. (CABA) a Strong Momentum Stock: Buy Now?
CABA

Zacks Investment Research
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?
CABAJanuary 27, 2026
Zacks Investment Research
Is Cabaletta Bio (CABA) Outperforming Other Medical Stocks This Year?
CABA

Business Wire
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
CABAJanuary 12, 2026
Business Wire
IND Amendment Clearance Obtained for Clinical Manufacturing of Rese-Cel from Cabaletta Bio Using Cellares' Automated Platforms
CABA

CNBC
TipRanks reveals the top 10 health care sector analysts of the past decade
CABAMay 21, 2023
CNBC
TipRanks reveals the top 10 health care sector analysts of the past decade
CABA
About Cabaletta Bio, Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees154
CEODr. Steven A. Nichtberger M.D.
IPO DateOct 25, 2019
HeadquartersPhiladelphia, PA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Steven A. Nichtberger M.D. | Co-Founder, Chairman, CEO & President | 1961 |
| Dr. Michael C. Milone M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board | — |
| Dr. Aimee Payne M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board | — |
| Mr. Anup Marda M.B.A. | Chief Financial Officer | 1978 |
| Dr. David J. Chang FACR, M.D., M.P.H. | Chief Medical Officer | 1963 |
| Dr. Gwendolyn K. Binder Ph.D. | President of Science & Technology | 1975 |
| Dr. Qing Sarah Yuan Ph.D. | Chief Technology Officer | 1971 |
| Dr. Samik Basu M.D. | Chief Scientific Officer | — |
| Mr. Michael Gerard J.D. | General Counsel & Secretary | 1980 |
| Ms. Heather Harte-Hall M.Sc. | Chief Compliance Officer | — |
Fundamentals
Valuation
Price-to-book value1.10
Profitability
Return on Equity-128.00%
Return on Assets-96.00%
EBITDA$-159.94M
Trading
Average volume5,015,679
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 41.20
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- -0.19
- MACD histogram
- 0.04
- SMA 50
- $2.02
- Price below SMA 50
- EMA 50
- $1.90
- Price below EMA 50
- SMA 200
- $2.81
- Price below SMA 200
- EMA 200
- $2.52
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
67% Buy
33% Hold
0% Sell
Analyst price target
- Low
- $3.00
- Average
- $9.00
- High
- $16.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -4.1 | -65.7 | ||||||||||
| 2022 | -22.6 | -28.9 | -6.9 | -27.7 | -11.1 | -17.2 | +11.3 | -17.4 | -35.6 | +164.1 | +117.5 | +97.6 |
| 2023 | +29.7 | -25.8 | -0.8 | +22.8 | -11.5 | +15.5 | +10.8 | +12.1 | +14.3 | -4.5 | +8.8 | +41.7 |
| 2024 | -7.6 | +11.2 | -28.8 | -36.7 | -17.9 | -25.3 | -9.1 | -18.2 | -6.7 | -23.5 | +3.0 | -45.0 |
| 2025 | +2.6 | -23.3 | -16.8 | +12.8 | +49.6 | -26.2 | -2.6 | +0.7 | +61.4 | +56.3 | -14.6 | -9.9 |
| 2026 | +16.3 | +32.8 | -18.5 | +11.6 | +28.6 | -15.3 | -10.4 | +15.6 | -41.8 | -20.1 | +1.4 |
Compare stocks
Market cap
$312.79M
-
-
-
Price / Earnings ratio
-1.70
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
5,015,679
-
-
-
Earnings per share
$-1.36
-
-
-



